Login to Your Account



Regeneron gets stay on Praluent, but Eylea guidance light

By Marie Powers
News Editor

Thursday, February 9, 2017

Regeneron Pharmaceuticals Inc. reported fourth-quarter and full-year 2016 sales gains for Eylea (aflibercept) but surprised the Street with lighter than expected 2017 guidance, projecting single-digit percentage growth compared to the consensus forecast of 12 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription